指南与共识白血病

儿童治疗相关AML的结局改善与治疗指导:AML-BFM研究组推荐

Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations.
指南 / 共识 · Blood Adv · 2025-01-01

该研究分析了1993至2019年间AML-BFM研究组中央诊断的119例2-20岁儿童治疗相关急性髓系白血病(tAML)患者,比较其与原发性AML的临床病理差异及预后因素。tAML生存率从AML-BFM 1993/1998方案的10%±6%提升至2012/2017登记处的50%±10%,但仍差于原发性AML;2个诱导疗程后无白血病证据(NEL;原始细胞<5%)时行造血干细胞移植(HSCT)可大幅改善生存。不良细胞遗传学、既往电离辐射(>35 Gy)和潜伏期≤1年是最强的预后不良因素。

要点

  • tAML生存率从1993/1998的10%±6%改善至2012/2017的50%±10%,但仍差于原发性AML。
  • 2个诱导疗程后NEL(原始细胞<5%)时行HSCT大幅改善生存。
  • 不良细胞遗传学、既往放疗>35 Gy、潜伏期≤1年为最强预后不良因素。

核心结论

  • 过去26年儿童tAML的结局和生存显著改善。
  • 2个诱导疗程后NEL时行HSCT是改善生存最有希望的治疗方法。
  • 放疗、不良细胞遗传学和潜伏期≤1年应视为儿童tAML的预后不良因素。

研究设计与样本

  • AML-BFM研究组对1993至2019年间中央诊断的119例2-20岁儿童tAML患者进行临床和病理分析。

主要发现

  • 与原发性AML相比,tAML与白细胞计数降低和中枢神经系统受累相关。
  • tAML潜伏期与原发性恶性肿瘤诊断时年龄呈负相关。
  • tAML患者更常见异常核型,KMT2A重排、不良细胞遗传学-7/del(7q)、复杂和单体核型过表达,而核心结合因子AML低表达。
  • 分层相关分子遗传学发生率与原发性AML相当,但tAML中无CEBPAdm。
  • tAML生存率从AML-BFM 1993/1998的10%±6%改善至2012/2017登记处的50%±10%,但仍差于原发性AML。

关键数值与推荐

  • 2个诱导疗程后NEL(原始细胞<5%)时行HSCT大幅改善生存。
  • 不良细胞遗传学、既往电离辐射(>35 Gy)和潜伏期≤1年被确定为最强预后不良因素。

临床怎么用

  • 作者建议2个诱导疗程后NEL时行HSCT作为改善生存最有希望的治疗方法。
  • 作者认为放疗、不良细胞遗传学和潜伏期≤1年应视为儿童tAML的预后不良因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related acute myeloid leukemia (AML; tAML) is one of the most feared therapy-emergent complications. This study aims to determine the clinical and pathological significance and define therapeutic implications and poor prognosticators in pediatric tAML. We analyzed a total of 119 pediatric patients (aged 2-20 years) who were centrally diagnosed with tAML within the Acute Myeloid Leukemia Berlin-Frankfurt-Münster (AML-BFM) study group between 1993 and 2019. Compared with de novo AML, tAML was associated with decreased white blood count and involvement of the central nervous system. Latency to tAML was inversely correlated with age at primary malignancy. Patients with tAML were more likely to have abnormal karyotypes, overrepresenting KMT2A rearrangements, the unfavorable cytogenetics -7/del(7q), as well as complex and monosomal karyotypes, whereas core-binding AML was underrepresented. The occurrence of stratification-relevant molecular genetics was comparable with de novo AML, whereas CEBPAdm was absent in tAML. Survival rates in tAML improved from 10% ± 6% in AML-BFM 1993/1998 to 50% ± 10% in the registries 2012/2017; however, this is still worse than de novo AML. Hematopoietic stem cell transplantation (HSCT) in no evidence of leukemia (NEL; <5% blasts) after 2 induction cycles greatly improved survival. Adverse cytogenetics, previous ionizing radiation (>35 Gy), and latency ≤1 year were identified as the strongest poor prognosticators. Over the past 26 years, outcome and survival significantly improved in pediatric tAML. Our results suggest that HSCT in NEL after 2 induction cycles is the most promising therapeutic approach for achieving improved survival. Radiation, adverse cytogenetics, and latency ≤1 year should be considered as poor prognosticators in pediatric tAML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Sendker S, Schneider M, Antoniou E, et al. Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations. Blood Adv. 2025. PMID: 39969195. doi:10.1182/bloodadvances.2024014728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。